CS276439B6 - Pharmaceutical for treating auto-immune diseases - Google Patents

Pharmaceutical for treating auto-immune diseases Download PDF

Info

Publication number
CS276439B6
CS276439B6 CS902689A CS268990A CS276439B6 CS 276439 B6 CS276439 B6 CS 276439B6 CS 902689 A CS902689 A CS 902689A CS 268990 A CS268990 A CS 268990A CS 276439 B6 CS276439 B6 CS 276439B6
Authority
CS
Czechoslovakia
Prior art keywords
animals
cells
group
proteoglycan
carbon atoms
Prior art date
Application number
CS902689A
Other languages
Czech (cs)
English (en)
Other versions
CS268990A3 (en
Inventor
Manuel Dr Modolell
Gerhard Prof Dr Munder
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of CS268990A3 publication Critical patent/CS268990A3/cs
Publication of CS276439B6 publication Critical patent/CS276439B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
CS902689A 1989-06-02 1990-05-31 Pharmaceutical for treating auto-immune diseases CS276439B6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3918082A DE3918082A1 (de) 1989-06-02 1989-06-02 Mittel gegen autoimmunerkrankungen

Publications (2)

Publication Number Publication Date
CS268990A3 CS268990A3 (en) 1992-01-15
CS276439B6 true CS276439B6 (en) 1992-05-13

Family

ID=6381972

Family Applications (1)

Application Number Title Priority Date Filing Date
CS902689A CS276439B6 (en) 1989-06-02 1990-05-31 Pharmaceutical for treating auto-immune diseases

Country Status (14)

Country Link
US (1) US5266564A (el)
EP (1) EP0474712B1 (el)
JP (1) JP2977894B2 (el)
AT (1) ATE94757T1 (el)
AU (1) AU5670690A (el)
CA (1) CA2056421C (el)
CS (1) CS276439B6 (el)
DE (2) DE3918082A1 (el)
DK (1) DK0474712T3 (el)
ES (1) ES2060173T3 (el)
GR (1) GR1001195B (el)
IE (1) IE64039B1 (el)
WO (1) WO1990014829A1 (el)
ZA (1) ZA904196B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3941009A1 (de) * 1989-12-12 1991-06-13 Medmark Pharma Gmbh Eliminierung von aktivierten lymphozyten
CA2243459C (en) * 1996-02-09 2002-09-17 Basf Aktiengesellschaft Human antibodies that bind human tnf.alpha.
US6583127B1 (en) 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents
SE9902155L (sv) * 1999-06-09 2000-12-10 Bjoern Rydevik Serum antibodies
JP2002228764A (ja) * 2001-02-02 2002-08-14 Fuji Photo Film Co Ltd 透光性シート体検出装置
US8324188B2 (en) 2006-11-10 2012-12-04 Vladimir Khazak Combinations of ET-18-O-CH3and anti-cancer agents for the treatment of cancer
ES2391659T3 (es) * 2006-11-10 2012-11-28 Radioprotect Alphaptose Ug(Haftungsbeschränkt) & Co. Kg Uso de compuestos de glicerol trisustituido para el tratamiento de lesiones por radiación
CN103816127A (zh) * 2006-11-10 2014-05-28 阿尔法普托斯有限公司 含有三取代甘油化合物的口服剂型
US8637688B2 (en) * 2006-12-20 2014-01-28 Julia Diederichs Topical dosage form comprising tri-substituted glycerol compounds
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2144618B1 (en) 2007-03-28 2013-05-15 Aker Biomarine ASA Bioeffective krill oil compositions
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
KR101343290B1 (ko) * 2007-08-29 2013-12-18 에이커 바이오마린 에이에스 새로운 크릴 밀 제조 방법
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
AU2016217566B2 (en) 2015-02-11 2019-02-14 Aker Biomarine Human Ingredients As Lipid compositions
KR20170118125A (ko) 2015-02-11 2017-10-24 에이커 바이오마린 앤탁틱 에이에스 지질 추출 공정

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2619686C2 (de) * 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
CH670763A5 (el) * 1985-08-02 1989-07-14 Seuref Ag
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose

Also Published As

Publication number Publication date
CS268990A3 (en) 1992-01-15
GR900100406A (en) 1991-11-15
IE901987L (en) 1990-12-02
WO1990014829A1 (de) 1990-12-13
ZA904196B (en) 1991-03-27
DE59002863D1 (de) 1993-10-28
CA2056421C (en) 2000-10-10
EP0474712B1 (de) 1993-09-22
EP0474712A1 (de) 1992-03-18
DE3918082A1 (de) 1991-01-24
DK0474712T3 (da) 1993-11-29
US5266564A (en) 1993-11-30
CA2056421A1 (en) 1990-12-03
ATE94757T1 (de) 1993-10-15
ES2060173T3 (es) 1994-11-16
IE64039B1 (en) 1995-06-28
GR1001195B (el) 1993-06-07
JP2977894B2 (ja) 1999-11-15
DE3918082C2 (el) 1992-02-06
AU5670690A (en) 1991-01-07
JPH04507096A (ja) 1992-12-10

Similar Documents

Publication Publication Date Title
CS276439B6 (en) Pharmaceutical for treating auto-immune diseases
Macdermott et al. Alterations of the immune system in ulcerative colitis and Crohn's disease
Kita et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Skelly et al. Making sense of the schistosome surface
Voorthuis et al. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon‐gamma in Lewis rats
Jain et al. Contribution of Porphyromonas gingivalis lipopolysachharide to periodontitis
US5013661A (en) Lipopolysaccharide-specific acyloxyacyl hydrolase
Harvey Cytolytic toxins
Fallon et al. Immune-dependent chemotherapy of schistosomiasis
EP0251134B1 (en) Compositions for preventing graft rejection
US4778788A (en) Agent against multiple sclerosis
Sher et al. Schistosomiasis: immunologic properties of developing schistosomula.
US7608246B2 (en) Apolipoprotein E as an adjuvant for lipid antigens
AU665764B2 (en) Methods and compositions for the prevention, diagnosis, and treatment of inflammatory serosal disease and related conditions
RU2083210C1 (ru) Средство для профилактической, поддерживающей и восстановительной терапии развивающихся при старении и/или под воздействием патогенных факторов патологий, связанных с дистрофическим и дегенеративными изменениями органов и тканей
Middlebrook Pathogenic Components of the Tubercle Bacillus: A Discussion of Recent Advances in Certain Fields of Tuberculosis Research and Postulation of Specific Component of the Tubercle Bacillus Determining Virulence
RAMSEY et al. Chemotaxis
Bräuer et al. Changes of immunoregulatory properties and induction of autoimmune reactivity to cartilage in rabbits with antigen-induced arthritis
Internationalis Bacteriology, immunology
Du Clos THE SUPPRESSOR CELL IN NEONATALLY INDUCED TOLERANCE.
Dion Septic shock, the second messenger system and the complement system
Ginsburg et al. Bayer-Symposium VI, Experimental Models of Chronic Inflammatory Diseases, 256-299 (1977) by Springer-Verlag 1977 Experimental Models of Streptococcal Arthritis: Pathogenetic Role of Streptococcal Products and
Smiley The immune response in rheumatoid synovitis
Weltzin Intracellular Calcium and Protein Kinase C Regulate Nonspecific Cell-Mediated Cytotoxicity by Mouse Lymphocytes (Calmodulin)
Li Molecular mechanisms controlling NF-κB activation in rheumatoid arthritis

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20080531